Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters

Thorax

Volumn 54, Issue 9, 1999, Pages 805-812

  Wang, Qingjian ^a   Wang, Yinjin ^a   Hyde, Dallas M ^a   Gotwals, Philip J ^b   Koteliansky, Victor E ^b   Ryan, Sarah T ^b   Giri, Shri N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BIOGEN   (United States)

Author keywords

Hamsters; Lung fibrosis; Transforming growth factor b (TGF ) soluble receptor

Indexed keywords

BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RECOMBINANT RECEPTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA RECEPTOR; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HAMSTER; HISTOPATHOLOGY; LUNG FIBROSIS; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032771311     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.9.805     Document Type: Article

References (57)

1. 1 Weissler JC. Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis. Am J Med Sci 1989;297:91-104.
2. 2 Bowden DH. Unraveling pulmonary fibrosis; the bleomycin model. Lab Invest 1984;50:487-8.
3. 3 Snider GL, Celli BR, Goldstein RH, et al. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am Rev Respir Dis 1978;117:289-97.
4. 4 Wang Q, Giri SN, Hyde DM, et al. Amelioration of bleomycin-induced pulmonary fibrosis in hamsters by combined treatment with taurine and niacin. Biochem Pharmacol 1991;42:1115-22.
5. 5 Wang Q, Hyde DM, Giri SN. Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin. Lab Invest 1992;67:234-42.
6. 6 Giri SN, Wang Q. Mechanisms of bleomycin-induced lung injury. Comments Toxicol 1989;3:145-76.
7. 7 Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-71.
8. 8 Raghu G, Masta S, Meyers D, et al. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta. Am Rev Respir Dis 1989;140:95-100.
9. 9 Coker RK, Laurent GJ, Shahzeidi S, et al. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol 1997;150:981-91.
10. 10 Raghow R, Postlethwaite AE, Keski-Oja J, et al. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987;79:1285-8.
11. 11 Penttinen RP, Kobayashi S, Bornstein P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 1988;85:1105-8.
12. 12 McAnulty RJ, Campa JS, Cambrey AD, et al. The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta 1991;1091:231-5.
13. 13 Raghow R, Lurie S, Seyer JM, et al. Profiles of steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J Clin Invest 1985;76:1733-9.
14. 14 Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther 1988;246: 765-71.
15. 15 Gurujeyalakshmi G, Hollinger MA, Giri SN. Regulation of transforming growth factor-beta 1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis. Am J Respir Cell Mol Biol 1998;18: 334-42.
16. 16 Khalil N, Bereznay O, Sporn M, et al. Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 1989;170:727-37.
17. 17 Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48: 959-66.
18. 18 Giri SN, Hyde DM, Braun RK, et al. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 1997;54:1205-16.
19. 19 Massague J. Receptors for the TGF-beta family. Cell 1992;69:1067-70.
20. 20 Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994;8:133-46.
21. 21 Ebner R, Chen RH, Lawler S, et al. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science 1993;262:900-2.
22. 22 Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-7.
23. 23 Vivien D, Attisano L, Wrana JL, et al. Signaling activity of homologous and heterologous transforming growth factor-beta receptor kinase complexes. J Biol Chem 1995;270: 7134-41.
24. 24 Lin HY, Moustakas A, Knaus P, et al. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem 1995;270:2747-54.
25. 25 Goetschy JF, Letourneur O, Cerletti N, et al. The unglycosylated extracellular domain of type-II receptor for transforming growth factor-beta. A novel assay for characterizing ligand affinity and specificity. Eur J Biochem 1996; 241:355-62.
26. 26 Tsang ML, Zhou L, Zheng BL, et al. Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII). Cytokine 1995;7: 389-97.
27. 27 di Clemente N, Wilson C, Faure E, et al. Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol Endocrinol 1994;8:1006-20.
28. 28 Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-22.
29. 29 Woessner JFJ. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-7.
30. 30 Giri SN, Misra HP, Chandler DB, et al. Increases in lung prolyl hydroxylase and superoxide dismutase activities during bleomycin-induced lung fibrosis in hamsters. Exp Mol Pathol 1983;39:317-26.
31. 31 Karlinsky JB, Goldstein CH. Fibrotic lung diseases: a perspective. J Lab Clin Med 1980;96:939-42.
32. 32 Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1-9.
33. 33 Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987;262:17467-74.
34. 34 Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90:1-7.
35. 35 Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
36. 36 Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 1994;8: 823-31.
37. 37 Santana A, Saxena B, Noble NA, et al. Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1995;13:34-44.
38. 38 Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996;49:461-9.
39. 39 Ghahary A, Shen YJ, Scott PG, et al. Enhanced expression of mRNA for transforming growth factor-beta, type I and type III procollagen in human post-burn hypertrophic scar tissues. J Lab Clin Med 1991;122:465-73.
40. 40 Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis 1993; 22:105-13.
41. 41 Broekelmann TJ, Limper AH, Colby TV, et al. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6.
42. 42 Sanvito F, Nichols A, Herrera PL, et al. TGF-beta 1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-alpha, triggers insulin-dependent diabetes. Biochem Biophys Res Commun 1995;217:1279-86.
43. 43 Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
44. 44 Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta 1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-76.
45. 45 Kelley J, Newman RA, Evans JN. Bleomycin-induced pulmonary fibrosis in the rat. Prevention with an inhibitor of collagen synthesis. J Lab Clin Med 1980;96:954-63.
46. 46 Miller RL, Udenfriend S. Hydroxylation of proline residues in collagen nascent chains. Arch Biochem Biophys 1970;139: 104-13.
47. 47 Glansbeck HL, van Beuningen HM, Vitters EL, et al. Expression of recombinant human soluble type II transforming growth factor-beta receptor in Pichia pastoris and Escherichia coli: two powerful systems to express a potent inhibitor of transforming growth factor-beta. Protein Expr Purif 1998;12:201-7.
48. 48 Komesli S, Vivien D, Dutartre P. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem 1998;254:505-13.
49. 49 Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465-75.
50. 50 Qi Z, Atsuchi N, Ooshima A, et al. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999;96:2345-9.
51. 51 Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 1998;30:293-8.
52. 52 Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
53. 53 Crippen TL, Riches DW, Hyde DM. Differential regulation of the expression of cytokine-induced neutrophil chemoattractant by mouse macrophages. Pathology 1998;66:24-32.
54. 54 Crippen TL, Klasing KC, Hyde DM. Regulation of cytokine-induced neutrophil chemoattractant in rat bone marrow-derived macrophages by inflammatory mediators. Pathobiology 1998;66:293-301.
55. 25 and PAF. J Clin Invest 1998;101:890-8.
56. 56 Wang Q, Haynam DR, Hyde DM,et al. Reduction of bleomycin-induced sequestration of neutrophils and vascular injury in hamster lungs by nitroglycerin. Inflammopharmacol 1992;1:249-61.
57. 57 Harris JA, Hyde DM, Wang Q, et al. Repeated episodes of C5a-induced neutrophil influx do not result in pulmonary fibrosis. Inflammation 1991;15:233-50.